Cover Image
市場調查報告書

抗核抗體 (ANA) 檢驗的全球市場的預測 ∼2021年:免疫螢光抗體法、ELISA、多工檢驗

Antinuclear Antibody Test Market by Product (Reagents & Assay Kits, Systems, Software, Services), Technique (Immunofluorescence, Elisa, Multiplex), Disease (Rheumatoid Arthritis, SLE), End User (Clinical Labs, Hospitals) - Forecast to 2021

出版商 MarketsandMarkets 商品編碼 371713
出版日期 內容資訊 英文 167 Pages
訂單完成後即時交付
價格
Back to Top
抗核抗體 (ANA) 檢驗的全球市場的預測 ∼2021年:免疫螢光抗體法、ELISA、多工檢驗 Antinuclear Antibody Test Market by Product (Reagents & Assay Kits, Systems, Software, Services), Technique (Immunofluorescence, Elisa, Multiplex), Disease (Rheumatoid Arthritis, SLE), End User (Clinical Labs, Hospitals) - Forecast to 2021
出版日期: 2016年09月21日 內容資訊: 英文 167 Pages
簡介

全球抗核抗體 (ANA) 檢驗的市場在預測期間內,預計以12.4%的年複合成長率發展,從2016年的8億2350萬美元,成長到2021年14億7610萬美元的規模。

本報告提供全球抗核抗體 (ANA) 檢驗的市場調查,市場及檢驗概要,影響市場成長因素與市場機會分析,各產品區分、技術、疾病、終端用戶、地區/主要國家趨勢與市場規模的變化與預測,競爭情形與市場佔有率,以及主要企業的簡介等彙整。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 市場概要
  • 生命週期分析:各地區

第5章 抗核抗體檢驗的全球市場:概要

  • 簡介
  • 市場區隔
  • 市場動態
    • 促進要素
    • 抑制因素
    • 市場課題
    • 趨勢

第6章 抗核抗體檢驗的全球市場:各產品分析

  • 簡介
  • 試劑、化驗套件
  • 系統
  • 軟體 & 服務

第7章 抗核抗體檢驗的全球市場:各技術分析

  • 簡介
  • ELISA
  • 免疫螢光抗體法
  • 多工檢驗

第8章 抗核抗體檢驗的全球市場:各疾病分析

  • 簡介
  • 類風濕性關節炎
  • 全身性紅斑性狼瘡
  • 乾燥症(修格蘭氏症候群)
  • 硬皮症
  • 其他

第9章 抗核抗體檢驗的全球市場:各終端用戶分析

  • 簡介
  • 醫院
    • 小規模
    • 中規模
    • 大規模
  • 臨床實驗室
  • 醫生的辦公室實驗室
  • 其他

第10章 抗核抗體檢驗的全球市場:各地區的分析

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
  • 亞洲
    • 中國
    • 日本
    • 印度
    • 其他
  • 其他地區

第11章 競爭環境

  • 簡介
  • 策略概要
  • 市場佔有率分析
  • 競爭情形、趨勢
    • 收購
    • 協定
    • 新產品的投入
    • 擴張
    • 其他

第12章 企業簡介

  • 簡介
  • THERMO FISHER SCIENTIFIC, INC.
  • ALERE INC.
  • BIO-RAD LABORATORIES, INC.
  • TRINITY BIOTECH PLC
  • ERBA DIAGNOSTICS, INC.
  • ANTIBODIES INC.
  • EUROIMMUN AG
  • IMMUNO CONCEPTS
  • INOVA DIAGNOSTICS
  • ZEUS SCIENTIFIC, INC.
    • 簡介
    • 產品與服務
    • 策略、分析師的見解
    • 發展趨勢
    • MnM的見解等

第13章 附錄

目錄
Product Code: MD 4588

The global antinuclear antibody (ANA) testing market is expected to reach USD 1,476.1 million by 2021 from USD 823.5 million in 2016, at a CAGR of 12.4%. The global ANA testing market is segmented based on products, diseases, techniques, end users, and regions. The assay kits & reagents segment is expected to register the highest growth rate in the ANA testing market, by product, during the forecast period. The high growth in this segment is attributed to the growing number of reagent rental agreements and increasing prevalence of autoimmune diseases worldwide.

Based on end users, the ANA testing market is segmented into clinical laboratories, hospitals, POLs, and other end users. The hospitals segment is expected to account for the largest share of the market in 2016. Increasing prevalence of autoimmune diseases, coupled with the fact that most diagnostic tests are performed in hospitals or hospital-attached laboratories, will be the major factors driving the growth of this market.

North America is the largest regional segment in the global ANA testing market, followed by Europe, Asia, and the Rest of the World (RoW). Growth in the North American market is primarily driven by the rising geriatric population and the growing number of people covered under medical insurance in the U.S.

In addition to comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. The company profiles in this report comprise the product portfolios, developments, and strategies adopted by players to maintain and increase their shares in the market. The abovementioned market research data, current market size, and forecast of future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the ANA testing market.

The major players in this market include Alere Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), ERBA Diagnostics, Inc. (U.S.), Trinity Biotech plc (Ireland), Thermo Fisher Scientific, Inc. (U.S.), Antibodies, Inc. (U.S.), EUROIMMUN AG (Germany), Immuno Concepts (U.S.), Inova Diagnostics (U.S.), and Zeus Scientific, Inc. (U.S.).

Objectives of the Study:

  • To define, describe, and forecast the global antinuclear antibody testing market on the basis of product, technique, disease, and end user
  • To provide detailed information regarding the major factors influencing market growth (drivers, restraints, opportunities, and trends)
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia, and the Rest of the World (RoW)
  • To strategically analyze the market structure and profile the key players operating in the global ANA testing market and comprehensively analyze their core competencies
  • To track and analyze competitive developments such as new product launches, agreements, expansions, and acquisitions in the global ANA testing market

Target Audience for this Report:

  • ANA Testing Instrument Manufacturers and Suppliers
  • Clinical Laboratories
  • Hospitals
  • Pharmaceutical and Biotechnology Companies
  • Academic Research Institutes Related to Antinuclear Antibody Testing

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. SECONDARY DATA
    • 2.1.1. KEY DATA FROM SECONDARY SOURCES
  • 2.2. PRIMARY DATA
    • 2.2.1. KEY DATA FROM PRIMARY SOURCES
  • 2.3. MARKET SIZE ESTIMATION
    • 2.3.1. BOTTOM-UP APPROACH
    • 2.3.2. TOP-DOWN APPROACH
  • 2.4. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CURRENT SCENARIO
  • 3.3. FUTURE OUTLOOK
  • 3.4. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. ANA TESTING MARKET OVERVIEW
  • 4.2. LIFE CYCLE ANALYSIS, BY REGION

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET SEGMENTATION
  • 5.3. MARKET DYNAMICS
    • 5.3.1. DRIVERS
      • 5.3.1.1. High Incidence of Autoimmune Diseases
      • 5.3.1.2. Increasing Population and Growth in Healthcare Expenditure
      • 5.3.1.3. Growth in the Number of Individuals Covered Under Medical Insurance
    • 5.3.2. RESTRAINTS
      • 5.3.2.1. Stringent Regulations for the Approval of Medical Devices
      • 5.3.2.2. Implementation of Excise Duty on Medical Devices in the U.S.
      • 5.3.2.3. Requirement of Significant Capital to Purchase High-cost Equipment
    • 5.3.3. OPPORTUNITIES
      • 5.3.3.1. Laboratory Automation
      • 5.3.3.2. Emerging Markets in Asia Present High-growth Opportunities
    • 5.3.4. TREND
      • 5.3.4.1. Reagent Rental Agreements

6. ANTINUCLEAR ANTIBODY TESTING MARKET, BY PRODUCT

  • 6.1. INTRODUCTION
  • 6.2. REAGENTS & ASSAY KITS
  • 6.3. SYSTEMS
  • 6.4. SOFTWARE & SERVICES

7. ANTINUCLEAR ANTIBODY TESTING MARKET, BY TECHNIQUE

  • 7.1. INTRODUCTION
  • 7.2. ELISA
  • 7.3. IMMUNOFLUORESCENCE ASSAY
  • 7.4. MULTIPLEX ASSAY

8. ANTINUCLEAR ANTIBODY TESTING MARKET, BY DISEASE

  • 8.1. INTRODUCTION
  • 8.2. RHEUMATOID ARTHRITIS
  • 8.3. SYSTEMIC LUPUS ERYTHEMATOSUS
  • 8.4. SJOGREN'S SYNDROME
  • 8.5. SCLERODERMA
  • 8.6. OTHER DISEASES

9. ANTINUCLEAR ANTIBODY TESTING MARKET, BY END USER

  • 9.1. INTRODUCTION
  • 9.2. HOSPITALS
    • 9.2.1. SMALL HOSPITALS
    • 9.2.2. MID-SIZED HOSPITALS
    • 9.2.3. LARGE HOSPITALS
  • 9.3. CLINICAL LABORATORIES
  • 9.4. PHYSICIAN OFFICE LABORATORIES
  • 9.5. OTHER END USERS

10. GEOGRAPHIC ANALYSIS

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. U.S.
    • 10.2.2. CANADA
  • 10.3. EUROPE
  • 10.4. ASIA
    • 10.4.1. CHINA
    • 10.4.2. JAPAN
    • 10.4.3. INDIA
    • 10.4.4. REST OF THE ASIA (ROA)
  • 10.5. REST OF THE WORLD

11. COMPETITIVE LANDSCAPE

  • 11.1. INTRODUCTION
  • 11.2. STRATEGIC OVERVIEW
  • 11.3. MARKET SHARE ANALYSIS
  • 11.4. COMPETITIVE SITUATION AND TRENDS
    • 11.4.1. ACQUISITIONS
    • 11.4.2. AGREEMENTS
    • 11.4.3. NEW PRODUCT LAUNCHES
    • 11.4.4. EXPANSIONS
    • 11.4.5. OTHER DEVELOPMENTS

12. COMPANY PROFILES (Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*

  • 12.1. INTRODUCTION
  • 12.2. THERMO FISHER SCIENTIFIC, INC.
  • 12.3. ALERE INC.
  • 12.4. BIO-RAD LABORATORIES, INC.
  • 12.5. TRINITY BIOTECH PLC
  • 12.6. ERBA DIAGNOSTICS, INC.
  • 12.7. ANTIBODIES INC.
  • 12.8. EUROIMMUN AG
  • 12.9. IMMUNO CONCEPTS
  • 12.10. INOVA DIAGNOSTICS
  • 12.11. ZEUS SCIENTIFIC, INC.

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. INSIGHTS OF INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.5. AVAILABLE CUSTOMIZATIONS
  • 13.6. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: PREVALENCE DATA FOR AUTOIMMUNE DISEASES
  • TABLE 2: HIGH INCIDENCE OF AUTOIMMUNE DISEASES TO DRIVE MARKET GROWTH
  • TABLE 3: IMPLEMENTATION OF EXCISE DUTY ON MEDICAL DEVICES IN THE U.S. TO RESTRAIN MARKET GROWTH
  • TABLE 4: GROWING DEMAND FOR LAB AUTOMATION TO OFFER MAJOR GROWTH OPPORTUNITIES
  • TABLE 5: REAGENT RENTAL AGREEMENTS ARE AN IMPORTANT TREND IN THE ANA TESTING MARKET
  • TABLE 6: ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 7: ANA TESTING MARKET SIZE FOR REAGENTS & ASSAY KITS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 8: ANA TESTING MARKET SIZE FOR SYSTEMS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 9: ANA TESTING MARKET SIZE FOR SOFTWARE & SERVICES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 10: ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 11: ANA TESTING MARKET SIZE FOR ELISA, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 12: ANA TESTING MARKET SIZE FOR IFA, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 13: ANA TESTING MARKET SIZE FOR MULTIPLEX ASSAYS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 14: ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY DISEASE, 2014-2021 (USD MILLION)
  • TABLE 15: ANA TESTING MARKET SIZE FOR RHEUMATOID ARTHRITIS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 16: ANA TESTING MARKET SIZE FOR SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 17: ANA TESTING MARKET SIZE FOR SJOGREN'S SYNDROME, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 18: ANA TESTING MARKET SIZE FOR SCLERODERMA, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 19: ANA TESTING MARKET SIZE FOR OTHER DISEASES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 20: ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 21: GLOBAL ANTINUCLEAR ANTIBODY TESTING MARKET SIZE FOR HOSPITALS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 22: ANA TESTING MARKET SIZE FOR HOSPITALS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 23: ANA TESTING MARKET SIZE FOR SMALL HOSPITALS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 24: ANA TESTING MARKET SIZE FOR MID-SIZED HOSPITALS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 25: ANA TESTING MARKET SIZE FOR LARGE HOSPITALS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 26: ANA TESTING MARKET SIZE FOR CLINICAL LABORATORIES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 27: ANA TESTING MARKET SIZE FOR PHYSICIAN OFFICE LABORATORIES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 28: ANA TESTING MARKET SIZE FOR OTHER END USERS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 29: ANA TESTING MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 30: NORTH AMERICA: ANA TESTING MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 31: NORTH AMERICA: ANA TESTING MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 32: NORTH AMERICA: ANA TESTING MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 33: NORTH AMERICA: ANA TESTING MARKET SIZE, BY DISEASE, 2014-2021 (USD MILLION)
  • TABLE 34: NORTH AMERICA: ANA TESTING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 35: U.S.: ANA TESTING MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 36: U.S.: ANA TESTING MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 37: U.S.: ANA TESTING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 38: CANADA: ANA TESTING MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 39: CANADA: ANA TESTING MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 40: CANADA: ANA TESTING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 41: EUROPE: ANA TESTING MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 42: EUROPE: ANA TESTING MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 43: EUROPE: ANA TESTING MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 44: EUROPE: ANA TESTING MARKET SIZE, BY DISEASE, 2014-2021 (USD MILLION)
  • TABLE 45: EUROPE: ANA TESTING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 46: ASIA: ANA TESTING MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 47: ASIA: ANA TESTING MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 48: ASIA: ANA TESTING MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 49: ASIA: ANA TESTING MARKET SIZE, BY DISEASE, 2014-2021 (USD MILLION)
  • TABLE 50: ASIA: ANA TESTING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 51: CHINA: ANA TESTING MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 52: CHINA: ANA TESTING MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 53: CHINA: ANA TESTING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 54: JAPAN: ANA TESTING MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 55: JAPAN: ANA TESTING MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 56: JAPAN: ANA TESTING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 57: INDIA: ANA TESTING MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 58: INDIA: ANA TESTING MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 59: INDIA: ANA TESTING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 60: ROA: ANA TESTING MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 61: ROA: ANA TESTING MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 62: ROA: ANA TESTING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 63: ROW: ANA TESTING MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 64: ROW: ANA TESTING MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION)
  • TABLE 65: ROW: ANA TESTING MARKET SIZE, BY TECHNIQUE, 2014-2021 (USD MILLION)
  • TABLE 66: ROW: ANA TESTING MARKET SIZE, BY DISEASE, 2014-2021 (USD MILLION)
  • TABLE 67: ROW: ANA TESTING MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 68: GROWTH STRATEGY MATRIX, 2013-2016
  • TABLE 69: ACQUISITIONS, 2013-2016
  • TABLE 70: AGREEMENTS, 2013-2016
  • TABLE 71: NEW PRODUCT LAUNCHES, 2013-2016
  • TABLE 72: EXPANSIONS, 2013-2016
  • TABLE 73: OTHER DEVELOPMENTS, 2013-2016

LIST OF FIGURES

  • FIGURE 1: MARKET SEGMENTATION
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4: ANA TESTING MARKET: BOTTOM-UP APPROACH
  • FIGURE 5: ANA TESTING MARKET: TOP-DOWN APPROACH
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: GLOBAL ANA TESTING MARKET SIZE, BY PRODUCT, 2016 VS. 2021 (USD MILLION)
  • FIGURE 8: GLOBAL ANA TESTING MARKET SIZE, BY TECHNIQUE, 2016 VS 2021 (USD MILLION)
  • FIGURE 9: GLOBAL ANA TESTING MARKET SIZE, BY DISEASE TYPE, 2016 VS 2021 (USD MILLION)
  • FIGURE 10: GLOBAL ANA TESTING MARKET SIZE, BY END USER, 2016 VS 2021 (USD MILLION)
  • FIGURE 11: GLOBAL ANA TESTING MARKET SIZE, BY REGION, 2016 VS 2021 (USD MILLION)
  • FIGURE 12: GLOBAL ANA TESTING MARKET TO WITNESS MODERATE GROWTH DURING THE FORECAST PERIOD
  • FIGURE 13: HOSPITALS SEGMENT TO DOMINATE THE GLOBAL ANA TESTING MARKET IN 2016
  • FIGURE 14: ASIA PROJECTED TO WITNESS THE FASTEST GROWTH DURING THE FORECAST PERIOD (2016-2021)
  • FIGURE 15: ASIAN MARKET SHOWCASES LUCRATIVE GROWTH OPPORTUNITIES
  • FIGURE 16: ANTINUCLEAR ANTIBODY TESTING MARKET SEGMENTATION
  • FIGURE 17: ANA TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & TRENDS
  • FIGURE 18: GLOBAL POPULATION DATA (2010-2015), IN BILLION
  • FIGURE 19: GLOBAL HEALTHCARE AND PUBLIC HEALTHCARE SPENDING, 2010-2015
  • FIGURE 20: GROWTH IN HEALTHCARE EXPENDITURE, BY REGION
  • FIGURE 21: REAGENTS & ASSAY KITS TO FORM THE LARGEST PRODUCT SEGMENT IN 2016
  • FIGURE 22: NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR REAGENTS & ASSAY KITS IN 2016
  • FIGURE 23: NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR SYSTEMS IN 2016
  • FIGURE 24: NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR SOFTWARE & SERVICES IN 2016
  • FIGURE 25: ELISA TECHNIQUE TO DOMINATE THE ANTINUCLEAR ANTIBODY TESTING MARKET IN 2016
  • FIGURE 26: NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR ELISA IN 2016
  • FIGURE 27: NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR IMMUNOFLUORESCENCE ASSAY IN 2016
  • FIGURE 28: NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR MULTIPLEX ASSAYS IN 2016
  • FIGURE 29: RHEUMATOID ARTHRITIS TO DOMINATE THE ANTINUCLEAR ANTIBODY TESTING MARKET, BY DISEASE, IN 2016
  • FIGURE 30: NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR RHEUMATOID ARTHRITIS IN 2016
  • FIGURE 31: NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN 2016
  • FIGURE 32: NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR SJOGREN'S SYNDROME IN 2016
  • FIGURE 33: NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR SCLERODERMA IN 2016
  • FIGURE 34: NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR OTHER DISEASES IN 2016
  • FIGURE 35: ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END USER, 2016 (USD MILLION)
  • FIGURE 36: GLOBAL ANTINUCLEAR ANTIBODY TESTING MARKET SIZE FOR HOSPITALS, BY TYPE, 2016 (USD MILLION)
  • FIGURE 37: NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR HOSPITALS IN 2016
  • FIGURE 38: NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR SMALL HOSPITALS IN 2016
  • FIGURE 39: NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR MID-SIZED HOSPITALS IN 2016
  • FIGURE 40: NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR LARGE HOSPITALS IN 2016
  • FIGURE 41: NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR CLINICAL LABORATORIES IN 2016
  • FIGURE 42: NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR PHYSICIAN OFFICE LABORATORIES IN 2016
  • FIGURE 43: NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR OTHER END USERS IN 2016
  • FIGURE 44: GLOBAL ECONOMIC INDICATORS (2005-2014)
  • FIGURE 45: GEOGRAPHIC SNAPSHOT OF THE ANTINUCLEAR ANTIBODY TESTING MARKET
  • FIGURE 46: ANA TESTING MARKET, BY REGION (MARKET SIZE AND GROWTH RATE)
  • FIGURE 47: NORTH AMERICA: ECONOMIC INDICATORS (2005-2014)
  • FIGURE 48: NORTH AMERICA: ANTINUCLEAR ANTIBODY MARKET SNAPSHOT, 2016
  • FIGURE 49: NORTH AMERICA: ANA TESTING MARKET, BY COUNTRY (MARKET SIZE AND GROWTH RATE)
  • FIGURE 50: REAGENTS & ASSAY KITS TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN NORTH AMERICA IN 2016
  • FIGURE 51: ELISA TECHNIQUE TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016
  • FIGURE 52: RHEUMATOID ARTHRITIS TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016
  • FIGURE 53: HOSPITALS TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKETS IN 2016
  • FIGURE 54: U.S.: ECONOMIC INDICATORS (2005-2014)
  • FIGURE 55: REAGENTS & ASSAY KITS TO ACCOUNT FOR THE LARGEST SHARE IN 2016
  • FIGURE 56: ELISA TECHNIQUE TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016
  • FIGURE 57: HOSPITALS TO DOMINATE THE ANA TESTING MARKET IN 2016
  • FIGURE 58: CANADA: ECONOMIC INDICATORS (2005-2014)
  • FIGURE 59: REAGENTS & ASSAY KITS TO ACCOUNT FOR THE LARGEST SHARE IN 2016
  • FIGURE 60: ELISA TECHNIQUE TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016
  • FIGURE 61: HOSPITALS TO DOMINATE THE ANA TESTING MARKET IN 2016
  • FIGURE 62: EUROPE: ECONOMIC INDICATORS (2005-2014)
  • FIGURE 63: EUROPE: ANA TESTING MARKET, BY COUNTRY (MARKET SIZE AND GROWTH RATE)
  • FIGURE 64: REAGENTS & ASSAY KITS TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016
  • FIGURE 65: ELISA TECHNIQUE TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016
  • FIGURE 66: RHEUMATOID ARTHRITIS TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016
  • FIGURE 67: HOSPITALS TO DOMINATE THE ANA TESTING MARKET IN 2016
  • FIGURE 68: ASIA: ECONOMIC INDICATORS (2005-2014)
  • FIGURE 69: ASIA: ANTINUCLEAR ANTIBODY MARKET SNAPSHOT, 2016
  • FIGURE 70: ASIA: ANA TESTING MARKET, BY COUNTRY (MARKET SIZE AND GROWTH RATE)
  • FIGURE 71: REAGENTS & ASSAY KITS TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016
  • FIGURE 72: ELISA TECHNIQUE TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016
  • FIGURE 73: RHEUMATOID ARTHRITIS TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016
  • FIGURE 74: HOSPITALS TO DOMINATE THE ANA TESTING MARKET IN 2016
  • FIGURE 75: CHINA: ECONOMIC INDICATORS (2005-2014)
  • FIGURE 76: REAGENTS & ASSAY KITS TO ACCOUNT FOR THE LARGEST SHARE IN 2016
  • FIGURE 77: ELISA TECHNIQUE TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016
  • FIGURE 78: HOSPITALS TO DOMINATE THE ANA TESTING MARKET IN 2016
  • FIGURE 79: JAPAN: ECONOMIC INDICATORS (2005-2014)
  • FIGURE 80: REAGENTS & ASSAY KITS TO ACCOUNT FOR THE LARGEST SHARE IN 2016
  • FIGURE 81: ELISA TECHNIQUE TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016
  • FIGURE 82: HOSPITALS TO DOMINATE THE ANA TESTING MARKET IN 2016
  • FIGURE 83: INDIA: ECONOMIC INDICATORS (2005-2014)
  • FIGURE 84: REAGENTS & ASSAY KITS TO ACCOUNT FOR THE LARGEST SHARE IN 2016
  • FIGURE 85: ELISA TECHNIQUE TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016
  • FIGURE 86: HOSPITALS TO DOMINATE THE ANA TESTING MARKET IN 2016
  • FIGURE 87: REAGENTS & ASSAY KITS TO ACCOUNT FOR LARGEST SHARE IN 2016
  • FIGURE 88: ELISA TECHNIQUE TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016
  • FIGURE 89: HOSPITALS TO DOMINATE THE ANA TESTING MARKET IN 2016
  • FIGURE 90: ROW: ANA TESTING MARKET, BY COUNTRY (MARKET SIZE AND GROWTH RATE)
  • FIGURE 91: REAGENTS & ASSAY KITS TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016
  • FIGURE 92: ELISA TECHNIQUE TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016
  • FIGURE 93: RHEUMATOID ARTHRITIS TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016
  • FIGURE 94: HOSPITALS TO DOMINATE THE ANA TESTING MARKET IN 2016
  • FIGURE 95: NEW PRODUCT LAUNCHES, ACQUISITIONS, AND AGREEMENTS-KEY GROWTH STRATEGIES ADOPTED BY PLAYERS IN THE ANA TESTING MARKET
  • FIGURE 96: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014
  • FIGURE 97: FINANCIAL PERFORMANCES OF THE LEADING MARKET PLAYERS
  • FIGURE 98: THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
  • FIGURE 99: ALERE INC.: COMPANY SNAPSHOT
  • FIGURE 100: BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
  • FIGURE 101: TRINITY BIOTECH PLC: COMPANY SNAPSHOT
  • FIGURE 102: ERBA DIAGNOSTICS, INC.: COMPANY SNAPSHOT
Back to Top